Journal of Clinical Oncology
Articles in this Issue
Real-world outcomes and prognostic factors for immune checkpoint inhibitors in dMMR/MSI-H metastatic colorectal cancer (mCRC).
101 Background: Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) status predicts response to i...
Early analysis of activity in esophageal cancer during phase 1 dose escalation of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participants with advanced HER2+ and HER2 low solid tumors.
355 Background: IKS014 is an ADC targeting HER2 that comprises a humanized IgG1 antibody conjugated to the monomethyl auri...
Response adapted neoadjuvant therapy in gastric cancer (RANT-GC): A phase Ib feasibility trial.
TPS465 Background: Current US based guidelines for locally advanced gastric/esophageal adenocarcinoma (GEA) (LAGEA) recomm...
International and contrasting perspectives on early-onset colorectal cancer: Awareness, testing, and research priorities of survivors and caregivers.
59 Background: Early-onset colorectal cancer (EOCRC) incidence is increasing worldwide, yet little is known about regional...
RIVER-mPDAC: A phase 2b/3 study of ponsegromab for the treatment of cachexia in patients with metastatic pancreatic ductal adenocarcinoma receiving first-line chemotherapy.
TPS791 Background: Ponsegromab is a humanized monoclonal antibody targeting growth differentiation factor 15 (GDF-15), a c...
Phase II trial of adjuvant toripalimab in stage IIb, IIc, or III colon cancer with mismatch repair deficiency.
TPS269 Background: Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer-related m...
Open versus minimally invasive surgery for large type 3 and type 4 gastric cancer: A multicenter retrospective study from high-volume centers in Japan.
383 Background: The optimal surgical approach for large type 3 and type 4 gastric cancers remains controversial. The objec...
Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01.
LBA285 Background: HERIZON-GEA-01 (NCT05152147) is a global, open-label, phase 3 trial of zanidatamab (dual HER2-targeted...
Modeling analysis of RATIONALE-305: Impact of peritoneal metastasis (PM) representation on clinical outcomes in patients (pts) treated with tislelizumab plus chemotherapy (TIS+CT) with gastric cancer/gastroesophageal junction cancer (GC/GEJC).
378 Background: RATIONALE-305 (NCT03777657) enrolled the highest number of pts with PM among similar trials and stratified...
Primary squamous cell carcinoma of the small intestine: A population-based study.
800 Background: Primary squamous cell carcinoma (SCC) of the small intestine is exceedingly rare and associated with poor...
Clinical performance of an improved colorectal cancer (CRC) screening blood test.
22 Background: Blood testing for CRC screening is a non-invasive option that could improve suboptimal adherence. One such...
A single institutional experience on patterns of ivermectin and fenbendazole use among patients with gastrointestinal cancers.
818 Background: The use of ivermectin and fenbendazole as supplemental therapy for cancer treatments have become increasin...
A multicenter phase II trial of ramucirumab plus irinotecan in patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S-1 therapy: RAMIEL trial (OGSG1901).
358 Background: There is no established chemotherapy for patients with early recurrence during or within 6 months after co...
A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, in subjects with advanced pancreatic cancer.
702 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly immunosuppressive tumor microenvironm...
Results from the safety lead-in for a phase 1b/2 study of ivosidenib plus durvalumab and gemcitabine/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation.
558 Background: Cholangiocarcinomas (CCAs) are rare cancers that are often advanced and incurable at diagnosis. Durvalumab...
Comparison of universal germline sequencing in White vs. minority populations with primary gastrointestinal malignancies.
817 Background: Universal germline sequencing is increasingly utilized in practice, but existing evidence and guidelines a...
Racial disparities in advanced hepatocellular carcinoma (aHCC) patients treated with atezolizumab plus bevacizumab (A+B): A real-world evidence study.
514 Background: A+B is established as the standard first-line therapy for patients with aHCC. However, there is a paucity...
Multi-institutional retrospective study of IDH2-mutated cholangiocarcinoma.
567 Background: IDH2 mutation is rare (1%) in patients (pts) with cholangiocarcinoma and there are no...
A phase II randomized study of atezolizumab plus multikinase inhibitor (MKI) versus MKI alone in patients with advanced hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab (Atezo/Bev).
554 Background: Atezo/Bev is the 1 st -line standard for advanced hepatocellular c...
Survival and safety outcomes of first-line immune checkpoint inhibitor combinations versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A meta-analysis.
580 Background: Hepatocellular carcinoma (HCC) is a highly fatal malignancy often diagnosed at advanced stage, with limite...
Sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable HCC (START-FIT using STRIDE): A single-arm, phase II, multi-centre study.
540 Background: START-FIT (sequential transarterial chemoembolization, stereotactic body radiotherapy, plus anti-PD-L1 and...
SGLT2 inhibitors and outcomes in pancreatic cancer: A large-scale propensity-matched cohort study.
687 Background: Pancreatic cancer (PC) carries high mortality and limited therapeutic options. Sodium-glucose cotransporte...
Prognostic nutritional index as a predictor of survival in metastatic gastroesophageal cancer patients treated with immunotherapy.
439 Background: The prognostic value of Prognostic Nutritional Index (PNI), which reflects both the nutritional and immuno...
Leveraging large language models (LLM) to guide adjuvant chemotherapy (AC) recommendations in stage III colorectal cancer (CRC).
103 Background: Clinicians spend significant time extracting and synthesizing information to risk-stratify and make adjuva...
Clinical outcomes and immune contexture in SMARCA4-deficient gastric cancer patients.
424 Background: Exploiting vulnerabilities in SWI/SNF chromatin remodeling complexes for cancer therapy is a promising the...